CYTK supply chain intelligence for Cytokinetics, Incorporated: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Cytokinetics, Incorporated (CYTK) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| RPRX | Royalty Pharma plc | 92% | We have entered into certain revenue participation right purchase agreements for omecamtiv mecarbil, aficamten, and CK-586 with affiliates of Royalty Pharma, pursuant to which such affiliates purchas… |
| RPRX | Royalty Pharma plc | 92% | Reciprocal relationship from RPRX graph: Reciprocal relationship from CYTK graph: We have entered into certain revenue participation right purchase agreements for omecamtiv mecarbil, aficamten, and C… |
| AZN | AstraZeneca PLC | 72% | Reciprocal relationship from AZN graph: Reciprocal relationship from CYTK graph: Reciprocal relationship from AZN graph: Reciprocal relationship from CYTK graph: Reciprocal relationship from AZN grap… |
| AZN | AstraZeneca PLC | 72% | ty contract manufacturers for our CMC and manufacturing needs. These third parties must comply with applicable regulatory requirements, including the FDA’s cGMP, the E.U.’s Guidelines on Good Distrib… |
| BMY | Bristol-Myers Squibb Company | 72% | ty contract manufacturers for our CMC and manufacturing needs. These third parties must comply with applicable regulatory requirements, including the FDA’s cGMP, the E.U.’s Guidelines on Good Distrib… |
| BMY | Bristol-Myers Squibb Company | 72% | Reciprocal relationship from BMY graph: Reciprocal relationship from CYTK graph: ty contract manufacturers for our CMC and manufacturing needs. These third parties must comply with applicable regulat… |
| BMYMP | Bristol-Myers Squibb Co | 72% | ty contract manufacturers for our CMC and manufacturing needs. These third parties must comply with applicable regulatory requirements, including the FDA’s cGMP, the E.U.’s Guidelines on Good Distrib… |
| BMYMP | Bristol-Myers Squibb Co | 72% | Reciprocal relationship from BMYMP graph: Reciprocal relationship from CYTK graph: ty contract manufacturers for our CMC and manufacturing needs. These third parties must comply with applicable regul… |
| MRK | Merck & Co., Inc. | 72% | ty contract manufacturers for our CMC and manufacturing needs. These third parties must comply with applicable regulatory requirements, including the FDA’s cGMP, the E.U.’s Guidelines on Good Distrib… |
| MRK | Merck & Co., Inc. | 72% | Reciprocal relationship from MRK graph: Reciprocal relationship from CYTK graph: Reciprocal relationship from MRK graph: Reciprocal relationship from CYTK graph: Reciprocal relationship from MRK grap… |
| NVSEF | Novartis AG | 72% | ty contract manufacturers for our CMC and manufacturing needs. These third parties must comply with applicable regulatory requirements, including the FDA’s cGMP, the E.U.’s Guidelines on Good Distrib… |
| NVSEF | Novartis AG | 72% | Reciprocal relationship from NVSEF graph: Reciprocal relationship from CYTK graph: ty contract manufacturers for our CMC and manufacturing needs. These third parties must comply with applicable regul… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from CYTK graph: ging pharmacology could result in an expansion of our business franchise with the development and potential approval… |
| SNYNF | Sanofi | 72% | ging pharmacology could result in an expansion of our business franchise with the development and potential approval of ulacamten for the treatment of a subset of patients with HFpEF whose hypercontr… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CUSTOMER-A | CUSTOMER-A | 90% | The following customers accounted for over 10% of total gross product revenue during the three months ended March 31, 2026. |
| CUSTOMER-B | CUSTOMER-B | 90% | The following customers accounted for over 10% of total gross product revenue during the three months ended March 31, 2026. |
| CUSTOMER-C | CUSTOMER-C | 90% | The following customers accounted for over 10% of total gross product revenue during the three months ended March 31, 2026. |
| AZN | AstraZeneca PLC | 72% | ging pharmacology could result in an expansion of our business franchise with the development and potential approval of ulacamten for the treatment of a subset of patients with HFpEF whose hypercontr… |
| AZN | AstraZeneca PLC | 72% | Reciprocal relationship from AZN graph: Reciprocal relationship from CYTK graph: Reciprocal relationship from AZN graph: Reciprocal relationship from CYTK graph: Reciprocal relationship from AZN grap… |
| BMY | Bristol-Myers Squibb Company | 72% | ging pharmacology could result in an expansion of our business franchise with the development and potential approval of ulacamten for the treatment of a subset of patients with HFpEF whose hypercontr… |
| BMY | Bristol-Myers Squibb Company | 72% | Reciprocal relationship from BMY graph: Reciprocal relationship from CYTK graph: Reciprocal relationship from BMY graph: Reciprocal relationship from CYTK graph: Reciprocal relationship from BMY grap… |
| BMYMP | Bristol-Myers Squibb Co | 72% | Reciprocal relationship from BMYMP graph: Reciprocal relationship from CYTK graph: Reciprocal relationship from BMYMP graph: Reciprocal relationship from CYTK graph: Reciprocal relationship from BMYM… |
| BMYMP | Bristol-Myers Squibb Co | 72% | ging pharmacology could result in an expansion of our business franchise with the development and potential approval of ulacamten for the treatment of a subset of patients with HFpEF whose hypercontr… |
| MRK | Merck & Co., Inc. | 72% | Reciprocal relationship from MRK graph: Reciprocal relationship from CYTK graph: ging pharmacology could result in an expansion of our business franchise with the development and potential approval o… |
| MRK | Merck & Co., Inc. | 72% | ging pharmacology could result in an expansion of our business franchise with the development and potential approval of ulacamten for the treatment of a subset of patients with HFpEF whose hypercontr… |
| NVSEF | Novartis AG | 72% | Reciprocal relationship from NVSEF graph: Reciprocal relationship from CYTK graph: ging pharmacology could result in an expansion of our business franchise with the development and potential approval… |
| NVSEF | Novartis AG | 72% | ging pharmacology could result in an expansion of our business franchise with the development and potential approval of ulacamten for the treatment of a subset of patients with HFpEF whose hypercontr… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from CYTK graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from CYTK graph: ging pharmacology could result in… |
| SNYNF | Sanofi | 72% | ging pharmacology could result in an expansion of our business franchise with the development and potential approval of ulacamten for the treatment of a subset of patients with HFpEF whose hypercontr… |
| BAYER-AG | BAYER-AG | 62% | 2024 and $ 0.3 million as of December 31, 2023. Collaboration for Commercialization of Aficamten in Japan On November 19, 2024, we announced that we had entered into a collaboration and license agree… |
| BAYER-CONSUMER-CARE-AG | BAYER-CONSUMER-CARE-AG | 62% | 2024 and $ 0.3 million as of December 31, 2023. Collaboration for Commercialization of Aficamten in Japan On November 19, 2024, we announced that we had entered into a collaboration and license agree… |
| CO-INC-BAYER-AG-ASTRAZENECA-PLC | CO-INC-BAYER-AG-ASTRAZENECA-PLC | 62% | tient diagnosis data, prescriptions and treatment data, has identified approximately 10,000 treaters, which represent an estimated ~75% of HCM cardiologist patient volume, enabling us to design an ef… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| CYTK-DEBT-9002 | Warrants outstanding: 23065 | 90% | xbrl warrant detail from xbrl 2021-12-31. |
| CYTK-DEBT | Debt stack $275.6M | 90% | Market cache reports total debt of $275.6M. |
| CYTK-DEBT-9003 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2025-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| CYTK-OWNER-T-ROWE-PRICE-INVESTMENT-MANAGEME | T. Rowe Price Investment Management, Inc. | 90% | 13F overlay lists T. Rowe Price Investment Management, Inc. as top holder; 453 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| CCEP | Coca-Cola Europacific Partners PLC | 100.00 | 2 | |
| EDSA | Edesa Biotech, Inc. | 100.00 | 2 | |
| CCCC | C4 Therapeutics, Inc. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 | |
| AZN | AstraZeneca PLC | 100.00 | 1 | ['customer', 'supplier'] |
| CBIO | Crescent Biopharma, Inc. | 100.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 100.00 | 2 | |
| DEO | Diageo plc | 100.00 | 2 | |
| EMMA | Emmaus Life Sciences, Inc. | 100.00 | 2 | |
| ANRO | Alto Neuroscience, Inc. | 100.00 | 2 | |
| BNBX | BNB Plus Corp. | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| ALXO | ALX Oncology Holdings Inc. | 100.00 | 2 | |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | 100.00 | 2 | |
| BLRX | BioLineRx Ltd. | 100.00 | 2 | |
| IMMP | Immutep Limited | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| BEAM | Beam Therapeutics Inc. | 100.00 | 2 | |
| CHRS | Coherus Oncology, Inc. | 100.00 | 2 |